Physician profile
Mark A Leiker
NPI 1881698348
$19,744.48
in general payments reported to CMS, 2019-2025
66 companies · $2,945 in 2025
The $2,945 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,951 · 2020: $2,332 · 2021: $3,434 · 2022: $2,930 · 2023: $3,075 · 2024: $3,077 · 2025: $2,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,096.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,184.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,957.96 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,863.03 | 2019-2025 | |
| Pfizer INC. | $1,751.19 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,475.78 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $911.37 | 2019-2025 | Evenity, Repatha, Otezla |
| Supernus Pharmaceuticals, INC. | $820.94 | 2020-2024 | Qelbree, Qelbree, Tlando |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $805.86 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $689.47 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $641.17 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $621.66 | 2019-2025 | Xarelto, Spravato |
| Sanofi-Aventis U.S. LLC | $596.48 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $421.20 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Antares Pharma, INC. | $381.63 | 2020-2025 | Xyosted, Tlando, Nocdurna |
| Radius Health, INC. | $331.72 | 2019-2025 | Tymlos |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Leiker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.